To print: Select File and then Print from your browser's menu

Title: Nisoldipine-Extended Release, Amlodipine Comparable In Safety, Efficacy For Hypertensive And Angina Therapy

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12565082&dopt=Abstract

American Journal of Cardiology 2003;91:3:274 -279. "Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris."
02/20/2003 09:09:36 AM
By Veronica Rose

Nisoldipine-extended release and amlodipine are well-tolerated, safe and effective therapies for patients with hypertension and chronic stable angina pectoris say researchers in the United States. Clinicians at Florida's University College of Medicine in Gainesville undertook a multi-centre randomised, double- blind, double-dummy, parallel group titration-to-effect study of nisoldipine-extended release (ER) and amlodipine in patients with stage 1 to 2 systemic hypertension (diastolic BP 90-109mm Hg ) and chronic stable angina pectoris. One hundred and twenty patients underwent a 3-week placebo introductory period followed by the 6-week trial. The patients were assigned active therapy with either nisoldipine-extended release, 20 to 40 mg, or amlodipine, 5-10 mg, once daily, titrated as necessary after two weeks to attain a diastolic BP higher than 90 mmHg. At the end of the trial, the researchers noted that "the mean reduction in systolic /diastolic BP from baseline was 15/13 mm Hg with nisoldipine-ER and 13/11 mm Hg with amlodipine." There was no increase in the heart rate experienced from either drug and the frequency of anginal episodes was decreased by both. Infrequent episodes of adverse events, usually vasodilator-related such as headaches and peripheral oedema, occurred more frequently in the patients treated with nisoldipine-ER.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12565082&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.